Co-Irbesan 150mg/12,5mg 28 tablets — Made in Turkey — Free Delivery

Co-Irbesan tablets are indicated for the treatment of essential hypertension.

This fixed dose combination is indicated in adult patients whose blood pressure cannot be adequately controlled with irbesartan or hydrochlorothiazide alone.

Active ingredient: irbesartan; hydrochlorothiazide;

1 coated tablet contains irbesartan 150 mg and hydrochlorothiazide 12.5 mg irbesartan 300 mg and hydrochlorothiazide 12.5 mg;

Excipients: lactose, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, coating * Opadry Pink OY - 34948;

* Coating composition Opadry Pink OY - 34948: hydroxypropyl methylcellulose (2910), polyethylene glycol 400, titanium dioxide (E 171), iron oxide red (E 172).

Hypersensitivity to active substances or to any of the excipients, or to any substances that are derivatives of sulfonamides (hydrochlorothiazide is a substance derived from sulfonamides).

Severe renal failure (creatinine clearance <30 ml/min).

A stable form of hypokalemia, hypercalcemia.

Severe liver failure, cirrhosis and cholestasis.

Simultaneous use of the drug Ko-Irbesan® with drugs containing aliskerin in patients with diabetes and patients with moderate and severe kidney damage (glomerular filtration rate <60 ml / min / 1.73 m2).

Simultaneous use of the drug Co-Irbesan® with angiotensin converting enzyme (ACE) inhibitors in patients with diabetic nephropathy.

Treatment-resistant hypokalemia or hypercalcemia.

Refractory hyponatremia.

Symptomatic hyperuricemia (gout).

Anuria.

During pregnancy and breastfeeding.

Childhood.

Ko-Irbesan® is used once a day, regardless of the meal.

Dose titration with the individual constituents (i.e. irbesartan and hydrochlorothiazide) may be recommended.

When clinically appropriate, the possibility of a direct transition from monotherapy to fixed combinations can be considered:

Co-Irbesan® 150 mg/12.5 mg can be used in patients whose blood pressure cannot be adequately controlled with hydrochlorothiazide alone or irbesartan 150 mg

Co-Irbesan® 300 mg/12.5 mg can be used in patients whose blood pressure is not adequately controlled by irbesartan at a dose of 300 mg of Co-Irbesan® 150 mg/12.5 mg.

Doses greater than 300 mg irbesartan/25 mg hydrochlorothiazide once daily are not recommended.

If necessary, Co-Irbesan® can be used with other antihypertensive drugs.

Contraindicated.

Contraindicated.

Carefully.

There is no specific information on the treatment of overdose with Co-Irbesan®.

The patient should be closely monitored and treatment should be symptomatic and supportive. Treatment depends on the time elapsed since the drug was used and the severity of the symptoms. Measures envisaged include: induce vomiting and or gastric lavage. In the treatment of overdose, activated charcoal can be used. It is necessary to frequently monitor the level of electrolytes and creatinine in the blood serum. If arterial hypotension occurs, the patient should be placed in a horizontal position and quickly apply saline solutions and replenish fluid volume.

From the nervous system: dizziness.

From the gastrointestinal tract: nausea / vomiting.

From the side of the kidneys and urinary system: violation of urination.

On the part of the vessels: orthostatic hypotension.

General disorders: increased fatigue.

From the skin and subcutaneous tissue: itching.

Alcohol. May lead to orthostatic hypotension.

Methyldopa. Isolated cases of hemolytic anemia have been reported with the simultaneous use of hydrochlorothiazide and methyldopa.

Salicylates. When using high doses of salicylates, hydrochlorothiazide may increase their toxic effects on the central nervous system.

Cyclosporine. With the simultaneous use of cyclosporine, hyperuricemia may increase and the risk of complications such as gout may increase.

Store below 25°C in original packaging.

Keep out of the reach of children.

Shelf life - 3 years.